IRIS
STELLA, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.096
EU - Europa 1.988
AS - Asia 1.609
SA - Sud America 351
AF - Africa 282
OC - Oceania 1
Totale 7.327
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.007
SG - Singapore 837
RU - Federazione Russa 710
IT - Italia 638
CN - Cina 404
BR - Brasile 320
IE - Irlanda 219
CI - Costa d'Avorio 184
IN - India 110
VN - Vietnam 88
UA - Ucraina 81
DE - Germania 80
CA - Canada 63
SN - Senegal 59
GB - Regno Unito 49
KR - Corea 44
FI - Finlandia 38
SE - Svezia 30
PL - Polonia 25
BE - Belgio 22
AR - Argentina 18
JP - Giappone 18
MX - Messico 17
ES - Italia 16
FR - Francia 16
TR - Turchia 16
IQ - Iraq 15
NL - Olanda 15
CZ - Repubblica Ceca 14
ZA - Sudafrica 14
BD - Bangladesh 12
UZ - Uzbekistan 11
HK - Hong Kong 10
ID - Indonesia 9
CH - Svizzera 8
NG - Nigeria 8
IL - Israele 7
AE - Emirati Arabi Uniti 6
AT - Austria 6
IR - Iran 6
MA - Marocco 6
GR - Grecia 5
EC - Ecuador 4
NO - Norvegia 4
TN - Tunisia 4
BJ - Benin 3
DO - Repubblica Dominicana 3
KZ - Kazakistan 3
PY - Paraguay 3
AZ - Azerbaigian 2
BG - Bulgaria 2
CO - Colombia 2
HU - Ungheria 2
KE - Kenya 2
LB - Libano 2
LT - Lituania 2
PE - Perù 2
RS - Serbia 2
SA - Arabia Saudita 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AU - Australia 1
EG - Egitto 1
GD - Grenada 1
GL - Groenlandia 1
HN - Honduras 1
IS - Islanda 1
JM - Giamaica 1
JO - Giordania 1
LV - Lettonia 1
MY - Malesia 1
NA - Namibia 1
NP - Nepal 1
PK - Pakistan 1
PS - Palestinian Territory 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
UY - Uruguay 1
VE - Venezuela 1
Totale 7.327
Salva come PNG Salva come JPEG
Città #
Singapore 521
Santa Clara 517
Dallas 474
Moscow 373
Chandler 326
Chicago 231
Dublin 219
Catania 185
Abidjan 184
Ashburn 154
Jacksonville 96
Beijing 90
Hefei 85
Boardman 84
Los Angeles 84
Kochi 79
Cambridge 60
Lawrence 59
Dakar 58
Andover 55
Civitanova Marche 54
New York 45
Seoul 43
Palermo 38
Grafing 35
Nanjing 34
Des Moines 30
Buffalo 29
São Paulo 29
Wilmington 29
Milan 28
The Dalles 27
Toronto 27
Dong Ket 26
Columbus 25
Brussels 22
Turku 22
Council Bluffs 19
Munich 19
Rome 19
Warsaw 19
Ho Chi Minh City 18
Tokyo 18
Hanoi 17
Montreal 17
Bari 16
Brno 13
Messina 13
San Mateo 13
Seattle 13
Johannesburg 12
Santa Venerina 12
Belo Horizonte 11
Chennai 11
Jiaxing 11
Lappeenranta 11
Nanchang 11
Ottawa 11
Rio de Janeiro 11
Boston 10
Falls Church 10
Orem 10
Stockholm 10
Aci Catena 9
Bremen 9
Brooklyn 9
London 9
Saint Petersburg 9
Abuja 8
Curitiba 8
Hong Kong 8
Amsterdam 7
Brasília 7
Hanover 7
Hebei 7
Manchester 7
Pune 7
Redmond 7
San Francisco 7
Tashkent 7
Atlanta 6
Jakarta 6
Phoenix 6
Poplar 6
Querétaro 6
Redondo Beach 6
Scottsdale 6
Fairfield 5
Florence 5
Frankfurt am Main 5
Giardini-Naxos 5
Helsinki 5
Houston 5
Manaus 5
Mascalucia 5
Miami 5
San Giovanni la Punta 5
Shenyang 5
Verona 5
Baghdad 4
Totale 5.070
Salva come PNG Salva come JPEG
Nome #
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 203
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment 156
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 153
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 147
AKT Inhibitors: New Weapons in the Fight Against Breast Cancer? 147
Biomarkers and prognostic factors for malignant pleural mesothelioma 144
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 144
Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily 143
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 142
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 141
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 141
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 137
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 134
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 133
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 132
A case of high-risk AML in a patient with advanced systemic mastocytosis 130
The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias 130
Effect of combined epigenetic treatments and ectopic NIS expression on undifferentiated thyroid cancer cells 129
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice 129
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22) 125
An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma 125
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 124
Rufloxacin induced photosensitization in bio-models of increasing complexity 119
Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity 119
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience 115
New insights in thyroid cancer and p53 family proteins 114
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report 113
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 108
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 108
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 107
Detection and clinical implications of a novel BCR-ABL1 E12A2 insertion/deletion in a CML patient expressing the E13A2 isoform 105
Double-face activity of resveratrol in voluntary runners: assessment of DNA damage by comet assay. 102
Opportunities and challenges of liquid biopsy in thyroid cancer 102
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 102
Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer 101
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 100
The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study 98
Correlates of Human Herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma 97
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far 96
Uncommon long-term survival in a patient with chronic myeloid leukemia 96
Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells 96
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma 95
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 94
Approcci Terapeutici Innovativi per il Trattamento di Cellule di Leucemia Mieloide Cronica Resistenti ad Imatinib Mesilato 93
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 93
In Silico Prediction of BRCA1 and BRCA2 Variants with Conflicting Clinical Interpretation in a Cohort of Breast Cancer Patients 91
Second-line dasatinib therapy improved compliance and deep molecular responses in imatinib-intolerant chronic myeloid leukemia patients 91
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 91
Targeting BCL-2 as a therapeutic strategy for primary p210BCR-ABL1-positive B-ALL cells 90
A Multiplex Assay for Fast PIK3CA Hotspot Mutation Characterization in a Single Specimen by 3-Color Digital PCR Analysis 88
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 85
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors 84
Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase 81
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 81
Diagnosis of Chronic Myeloid Leukemia Early in Pregnancy 80
Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51 80
THE ROLE OF SPARC IN CHRONIC MYELOID LEUKEMIA 79
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 77
No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level 73
High BCR-ABL/GUS(IS) Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib 72
Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia 72
The Role of New Technologies in Myeloproliferative Neoplasms 72
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance 69
Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer 68
REThinking the role of the RET oncogene in breast cancer 68
Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment 65
The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy 65
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia 63
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis 60
The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities 60
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain 56
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes 53
Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer 31
Totale 7.507
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.202
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.202
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021173 0 0 0 0 0 20 27 2 53 3 33 35
2021/2022435 20 67 11 7 78 8 64 15 25 11 30 99
2022/20231.036 68 82 56 119 58 148 13 201 209 14 46 22
2023/2024553 44 83 26 24 19 132 8 33 7 23 112 42
2024/20252.107 30 330 79 152 412 291 166 64 75 143 255 110
2025/20262.738 253 240 584 288 657 716 0 0 0 0 0 0
Totale 7.507